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Modulation of LAT1 (SLC7A5) 
transporter activity and stability by 
membrane cholesterol
David Dickens1,*, George N. Chiduza2,*, Gareth S. A. Wright2, Munir Pirmohamed1, 
Svetlana V. Antonyuk2 & S. Samar Hasnain2
LAT1 (SLC7A5) is a transporter for both the uptake of large neutral amino acids and a number of 
pharmaceutical drugs. It is expressed in numerous cell types including T-cells, cancer cells and brain 
endothelial cells. However, mechanistic knowledge of how it functions and its interactions with lipids 
are unknown or limited due to inability of obtaining stable purified protein in sufficient quantities. Our 
data show that depleting cellular cholesterol reduced the Vmax but not the Km of the LAT1 mediated 
uptake of a model substrate into cells (L-DOPA). A soluble cholesterol analogue was required for the 
stable purification of the LAT1 with its chaperon CD98 (4F2hc,SLC3A2) and that this stabilised complex 
retained the ability to interact with a substrate. We propose cholesterol interacts with the conserved 
regions in the LAT1 transporter that have been shown to bind to cholesterol/CHS in Drosophila 
melanogaster dopamine transporter. In conclusion, LAT1 is modulated by cholesterol impacting on its 
stability and transporter activity. This novel finding has implications for other SLC7 family members and 
additional eukaryotic transporters that contain the LeuT fold.
The L-Type Amino Acid Transporter 1 (LAT1,SLC7A5) is part of the SLC7 family and forms a heterodimer with 
CD98 via a disulphide bond1. CD98 (4F2hc,SLC3A2) is a type II glycoprotein that functions as a chaperone for 
LAT1, stabilising and facilitating its translocation to the plasma membrane. LAT1 is the functional unit of the 
complex2 and substrates include a range of large neutral amino acids such as tyrosine, leucine, isoleucine, valine 
and phenylalanine as well as pharmaceutical drugs including L-DOPA and gabapentin3,4.
LAT1 is expressed in many tissues of the body, functioning as a sodium independent antiporter with a 1:1 
stoichiometry5. LAT1 is highly expressed in brain endothelial cells, in the blood-brain barrier and in the inner 
blood retinal barrier6,7. LAT1 is a key transporter in the uptake of substrates into the brain and has been proposed 
as a target for enhanced delivery into the brain for new molecular entities8. LAT1 expression is also observed at 
the placenta suggesting a role for providing the essential amino acids needed for the growing foetus9. The global 
knockout of LAT1 in mice has been found to be embryonically lethal which could be due to its transport role 
at the placenta or because it is essential for cells in terms of the uptake of large neutral amino acids or both10. A 
conditional knock out of LAT1 in T-cells of mice has shown that it is the main L-type amino acid transporter in 
this cell type and is required for the metabolic reprogramming essential for T-cell differentiation11.
In many human tumours, LAT1 is highly overexpressed which is thought to play an important role in tumour 
growth and disease progression12. LAT1 has thus been proposed as a novel target for cancer treatment. An exam-
ple of this approach is the generation of a high affinity LAT1 inhibitor of (JPH203/ KYT-0353), that inhibits 
tumour growth in vivo and is currently undergoing a Phase I clinical trial in humans (UMIN000016546) as a 
novel adjuvant treatment approach for solid tumours13.
The mechanistic knowledge of how LAT1 functions as a transporter is based on our knowledge of the LeuT 
fold prokaryotic transporters of known structure despite their low sequence identity to LAT1 (<21%)14,15. From 
these low similarity homologues a predictive structure of LAT1 was generated and docked with a chemical library 
in silico which identified additional ligands16,17. This approach has proposed that LAT1 can transport substrates 
by the alternative-access mechanism where transporters undergo several conformational changes to translo-
cate the substrate across the plasma membrane3,16,17. The CD98 ectodomain structure has been solved by x-ray 
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crystallography18 but does not provide an insight into how the interaction between the two components of the 
heterodimer affect the transport cycle of LAT1. LAT2 (SLC7A8), which has 52.8% identity to LAT1, is stabilised 
by CD98 surrounding the extracellular regions of the transporter19.
Cholesterol is an important component of the plasma membrane of eukaryotic cells and comprises between 
20 to 40 mol% of the membrane20. It is a sterol with an essential role in maintaining membrane fluidity and can 
directly interact with integral membrane proteins21. Multiple studies with eukaryotic transporters in mammalian 
cells have shown that both the human serotonin transporter (hSERT) and human dopamine transporter (hDAT) 
are modulated in activity following either cholesterol depletion or addition22–24. In the case of hSERT, biochemical 
analyses have shown that cholesterol binding enhances the fraction of the transporter in the outward open con-
firmation while with the hDAT it stabilises the transporter in an outward open conformation23,25. Corroborating 
this, the outward open conformation was observed in the crystal structures of cholesterol or cholesteryl hemi-
succinate (CHS) bound Drosophila melanogaster dopamine transporter (dDAT) and hSERT26–28. The interaction 
with cholesterol or CHS was increased by mutations of dDAT and hSERT that also decreased the transport kinetic 
parameters while still retaining functional activity12,27.
Here we show that cholesterol modulates LAT1 stability and its transporter activity. We provide evidence 
that cholesterol/CHS interact with LAT1-CD98 and suggest that the LAT1 transporter has two cholesterol/CHS 
binding sites similar to the binding sites found in the dDAT.
Results
Modulation of cholesterol levels alters the LAT1 transport of L-DOPA. A time course for L-DOPA 
uptake into cells was performed in both HEK293 control cells and stably transfected HEK293 LAT1 cells, in order 
to validate the use of L-DOPA as a model LAT1 substrate (Fig. 1A). At all time points tested, a significant increase 
in uptake of L-DOPA was observed in the LAT1 stably transfected cells compared to the control cells. This finding 
is in agreement with previous studies that have shown L-DOPA to be a substrate of the LAT1 transporter4, by 
an uptake process that is both sodium independent and inhibited by 2-aminobicyclo-[2,2,1]-heptane-2-carbox-
ylic acid (BCH)29. L-DOPA was thus used as a model substrate of LAT1 in experiments investigating the role 
of cholesterol on LAT1 function. To deplete HEK293 cells of cholesterol, the cells were treated for 1 hour with 
methyl-β-cyclodextrin (MβCD). The relative amount of cholesterol in the cells was determined by a cholesterol 
quantification assay. There was observed a significant decrease in total cholesterol (cholesterol and cholesteryl 
ester) in the MβCD treated cells compared to the untreated cells (Fig. 1B). At 1 μM of L-DOPA, no significant dif-
ference in L-DOPA up take was detected between treated and untreated HEK293 LAT1 cells (Fig. 1C). However, 
at 1 mM L-DOPA a significant reduction in L-DOPA uptake was observed in MβCD treated LAT1 cells compared 
to the untreated LAT1 cells (Fig. 1D). Sulfobutylether-β-cyclodextrin (SBCD), a derivative of cyclodextrin which 
can interact with cholesterol but not extract it from the plasma membrane30, was utilised as a control. SBCD 
was rationally designed to improve its safety profile in vivo and part of this was the removal of the compounds 
ability to dimerises with itself. As such SBCD is unable to form the 2 to 1 molecular ratio with cholesterol that is 
required for depletion from the plasma membrane30. SBCD treatment was found not to alter the L-DOPA uptake 
significantly (Fig. 1E) which suggests that the cholesterol depletion effects of MβCD are required for its effect on 
L-DOPA uptake.
Cholesterol depletion alters the kinetics of LAT1 mediated transport. Given the effects of MβCD 
treatment on the activity of the LAT1 transporter, we investigated the LAT1 mediated kinetics at a range of 
L-DOPA concentrations at a linear time point (Fig. 2A). The data showed that MβCD treatment altered the kinet-
ics of LAT1 mediated transport (Table 1). The Vmax was significantly reduced in the treated cells (8506 pmoles/
million cells/min) compared to the untreated cells (13925 pmoles/million cells/min), but the Km of L-DOPA 
uptake between untreated (200 μM) and treated (148 μM) showed no significant difference. This finding could 
be caused by either alterations of the transport properties of the LAT1 protein or a change in the amount of the 
transporter at the plasma membrane.
To investigate whether MβCD treatment altered the localisation of the LAT1 transporter, cell surface prepa-
rations from untreated and treated cells were immunoblotted. No change in plasma membrane localisation of 
over expressed LAT1 was observed following MβCD treatment (Fig. 2B). This suggests that the change of uptake 
kinetics by LAT1 following cholesterol depletion by MβCD is not due to an alteration in the localisation of the 
transporter complex. From classical Michaelis-Menten kinetics parameters, a change in Vmax but not Km suggests 
a non-competitive inhibitor process, more precisely in this case, allosteric modulation31.
Figure 2B shows an upregulation of endogenous CD98 in response to increased LAT1 expression in HEK293 
cells, an observation initially reported by Khunweeraphong et al.32,33. Correspondingly, the knock out of LAT1 
leads to a reduction of CD98 protein levels32,33. This linkage of CD98 to LAT1 expression levels enables us to 
utilise cell lines that are only ectopically expressing the LAT1 transporter for protein studies of the LAT1-CD98 
heterodimer.
Detergent solubilised LAT1-CD98 complex is stabilised by a cholesterol analogue (CHS). To 
investigate if cholesterol interacts with human LAT1 directly, ectopically expressed protein from HEK293 GnTI- 
cells was solubilised in detergents with and without the water-soluble cholesterol analogue CHS before immuno-
affinity purification of LAT1-CD98. Distinct size-exclusion chromatography (SEC) profiles were observed with 
and without CHS (Fig. 3A). Peaks 1 and 3 had increased peak heights in presence of CHS. Additionally, peak 3 
with CHS had a shifted retention time compared with peak 3 in the purification without CHS. Each of the three 
peaks from the purification with CHS were immunoblotted for CD98 in non-reducing conditions and an over 
exposed immunoblot is shown (Fig. 3B). Despite the denaturing conditions of SDS-PAGE, a smear above 220 kDA 
was observed in peaks 1 and 2 that was not present in peak 3. This is suggestive of aggregation of the purified 
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Figure 1. Cholesterol depletion modulates L-DOPA transport in LAT1 overexpressing cells. (A) HEK293 
control and HEK293 LAT1 cells were incubated over a time course with 1 μM [3H]-L-dopa with uptake 
determined as pmoles per million cells and plotted against time (minutes). HEK293 cells stably transfected with 
pcDNA3.1 (control) or pcDNA3.1 LAT1 (LAT1) were preincubated with 10 mM methyl β cyclodextrin (MβCD) 
for 1 hour in serum free medium. (B) Total cholesterol (free and ester forms) were determined with a cholesterol 
quantification assay (fluorometric detection) and are shown relative to untreated control cells. Uptake of 1 μM 
(C) or 1 mM (D) [3H]-L-dopa was determined at a 3 minute time point in HEK293 control or HEK293 LAT1 
cells. (E) HEK293 control or HEK293 LAT1 cells were preincubated with 10 mM sulfobutylether-β-cyclodextrin 
(SBCD) for 1 hour in serum free medium. Uptake of 1 mM [3H]-L-dopa was determined at a 3 minute time 
point in HEK293 control or HEK293 LAT1 cells. Data shown are three independent experiments performed 
in triplicate and are expressed as mean ± SD (n = 3). Significantly different from control or untreated cells; 
*(P < 0.05), **(P < 0.01), ***(P < 0.001). No statistical significance is indicated by ns.
www.nature.com/scientificreports/
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proteins in peaks 1 and 2, thus all following experiments utilised peak 3 from purifications that contained CHS. 
Peak 3 was immunoblotted in non-reducing conditions for CD98 and His6 tagged LAT1. Both proteins of the 
heterodimer were detected and had the characteristic smear of a glycosylated protein (Fig. 3C). The immunoblots 
and coomassie stained SDS-PAGE gel reveal a band consistent with the 123 kDa molecular weight of the heterod-
imer (Fig. 3C). In order to further biochemically characterise the purified complex in near to native conditions, 
the complex was run on analytical SEC. A monodisperse peak corresponding to the LAT1-CD98 heterodimer 
was observed on day 1 (Fig. 3D). The SEC analysis was repeated 3 and 7 days after purification in order to deter-
mine stability of the purified LAT1-CD98 stored at 4 °C over time. The complex was kinetically stable in the SEC 
buffer for 3 and 7 days at 4 °C with no detectable aggregation or denaturation by analytical SEC (Fig. 3D). Taken 
together, the data from the immunoblots and chromatographic profiles produced from the analysis of peak 3, 
it can be concluded that CHS is necessary for successful purification of the LAT1-CD98 heterodimer.
To determine the thermal stability of the LAT1-CD98 complex, samples in SEC buffer were heated to temper-
atures between 4–100 °C and analysed by HPLC-SEC. The peak height and monodispersity of the LAT1-CD98 
samples decreased with increasing temperature (Fig. 3E). To quantify this, the normalised absorbance relative to 
the protein sample at 4 °C was plotted against temperature. A dose response curve to heating was obtained and the 
thermal stability of the LAT1-CD98 in SEC buffer was defined with the Tm found to be 47 °C (Fig. 3F).
CHS stabilised LAT1-CD98 complex interacts with leucine. Ligand studies were undertaken to deter-
mine the thermal and conformational stability of the purified LAT1-CD98, as an interaction with ligand can be an 
indirect indicator that the protein is correctly folded. Leucine was chosen for this purpose, as it absorbs ultraviolet 
light at 280 and 220 nm negligibly, and is stable in solution during the experimental time frame. The addition of 
leucine resulted in a 39% increase in the peak height at 10.4 mL (peak 3) in the SEC profile (Fig. 4A). To deter-
mine whether this increase was due to increased stability of LAT1-CD98, samples of LAT1-CD98 purified in the 
presence and absence of leucine were heat stressed at 60 °C for 10 mins and then analysed by HPLC-SEC (Fig. 4B). 
Figure 2. The kinetics of LAT1 mediated transport are altered by cholesterol depletion. (A) The LAT1 
mediated uptake of L-DOPA was determined ± preincubation with 10 mM MβCD for 1 hour in serum free 
medium. Following treatment, HEK293 control and HEK293 LAT1 cells were incubated in transport buffer  
with 1 μM–2000 μM of [3H]-L-DOPA. The L-DOPA uptake velocity in the HEK293 control cells was taken 
 away from L-DOPA uptake velocity in the HEK293 LAT1 cells to give a LAT1 mediated transport rate.  
The concentration of L-DOPA (μM) is plotted against the velocity of LAT1 mediated L-DOPA uptake  
(pmoles/minute/million cells). Data are expressed as mean ± SD (n = 3). Significantly different from  
untreated cells; **(P < 0.01). (B) Immunoblots for His6 tag, CD98 and Na+/K+ ATPase on cell surface 
preparations from HEK293 control or HEK293 LAT1 cells ± 10 mM MβCD treatment for 1 hour in  
serum free medium. Representative western blots are shown and full-length blots are presented in 
Supplementary Figure 1.
Untreated +MβCD
Vmax (pmoles/million cells/min) 13925 (923) 8506 (684)*
Km (μM) 200 (78) 148 (22)
Table 1.  Kinetics of LAT1 mediated transport ± MβCD treatment for the uptake of L-DOPA. Significantly 
different from untreated LAT1 mediated transport of L-DOPA *(P < 0.05). n = 3 with standard deviation in brackets.
www.nature.com/scientificreports/
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This showed a significantly decreased monodispersity in the absence of leucine and a 9% higher normalised 
absorbance in the presence of leucine, indicative of a thermal stabilising effect (Fig. 4C). The melting curve for 
LAT1-CD98 in the presence of leucine showed that the Tm increased to 57 °C (Fig. 4D) compared to 47 °C without 
leucine. This suggests that not only is CHS required for successful protein purification but that the purified pro-
tein retains its ability to interact with substrate compounds. However, it should be noted that this assay does not 
distinguish between specific and nonspecific interactions of leucine with the LAT1-CD98 heterodimer.
Figure 3. Cholesterol analogue (CHS) stabilises LAT1-CD98 during affinity purification. (A) LAT1 was 
purified by immunoaffinity precipitation utilising the V5 epitope from HEK293S GnTIˉ cells stably expressing 
pcDNA3.1 LAT1-V5-6xHis. Representative SEC profiles detected by absorbance at 280 nm are shown.  
(B) The peaks eluted at 8.4 mL (1), 9.5 ml (2) and 10.5 ml (3) from the SEC profile with CHS were analysed  
by immunoblotting for CD98 in non-reducing conditions. (C) Peak 3 from SEC was concentrated, run on  
SDS-PAGE then coomassie stained or immunoblotted for the His6 tag and CD98 in non-reducing conditions.  
(D) Stability of the purified LAT1-CD98 at 4 °C was monitored for up to 7 days after purification by 
analytical SEC. (E) The purified LAT1-CD98 was heated for 10 minutes at the indicated temperatures and 
run on analytical SEC. (F) The effect of the heat stress on the purified LAT1-CD98 was quantified from the 
chromatograms by calculating the normalised absorbance (n = 3). The normalised absorbance of the purified 
LAT1-CD98 was plotted against temperature with the melting point determined (Tm ± standard error).
www.nature.com/scientificreports/
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Conservation of cholesterol binding domains. To build on the experiments with cells and purified 
protein we investigated if the cholesterol/CHS binding sites of the dDAT are conserved in LAT1 by in silico 
methodologies. An alignment of LAT1 and dDAT was performed using PROMALS3D, which allows for the 
alignment of distantly related sequences by taking into account structural information, predicted or otherwise34. 
The two transporters have a low sequence identity of 19.6% but are predicted to share the same LeuT structural 
fold. Most of the cholesterol interacting residues in binding sites I (91%) and II (70%) of dDAT are identical, 
equivalent or have similar physico-chemical properties (conservation value > 5) to corresponding residues in 
LAT1 (Fig. 5A). To test whether these residues may have functional importance for the LAT1 transporter and are 
thereby conserved during evolution, we performed a multiple sequence alignment of LAT1 orthologues from a 
diverse group of 8 metazoans. Ten residues were identical and seven similar out of 17 residues, across both bind-
ing sites in the 8 orthologues (Fig. 5B). An alignment of LAT1 and LAT2 (Fig. 6) found residues comprising both 
of the cholesterol/CHS putative binding sites were conserved, with all residues having a conservation scores >7. 
The conserved residues were located on adjacent helices in the predicted 3D structure of LAT1 (Fig. 7B), which is 
consistent with the requirement for the cholesterol interacting residues in the binding sites to be in close proxim-
ity, as seen in the dDAT structures (Fig. 7A)26,27.
Discussion
LAT1 was first cloned in 1998, found to interact with CD98 via a disulphide bond and is the transport compo-
nent of the heterodimer1,2,17,35. To date our mechanistic knowledge of how LAT1 functions and interacts with 
substrates is derived from in silico models generated using low sequence similarity homologues from prokaryotes 
that have the LeuT fold14,15. These studies have been successful in identifying novel ligands and suggesting that 
the transporter acts by the alternative access mechanism17. However, to our knowledge, there are no experimental 
or modelling studies in the literature concerning the LAT1 transporter that take into account structural knowl-
edge gained from eukaryotic transporters with the conserved LeuT fold. As a result, structural insights to LAT1 
function resulting from its eukaryotic origin, have been missed. This is the first study to both model and test this 
experimentally for the human LAT1 transporter.
Figure 4. The effect of leucine on purification and thermal stability of LAT1-CD98. (A) SEC profiles of 
protein purification performed in the presence or absence of 50 mM leucine. (B) The effect of presence or 
absence of 50 mM leucine on the thermal stability of LAT1-CD98 was determined by heating stressing, at 60 °C 
for 10 minutes followed by HPLC-SEC analysis. (C) The effect of the heat stress on the purified LAT1-CD98, in 
the absence or presence of leucine was quantified by calculating the normalised absorbance (n = 3). Significant 
difference from purified LAT1-CD98 without leucine; **(P < 0.01). (D) The effect of the heat stress on the 
purified LAT1-CD98 with leucine was quantified from the analytical SEC profiles by calculating the relative 
peak intensity and normalised to the intensity at 4 °C (n = 3). The normalised absorbance for the peak intensity 
of the purified LAT1-CD98 with leucine was plotted against temperature with the melting point determined 
(Tm ± standard error).
www.nature.com/scientificreports/
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Figure 5. Putative conservation of the cholesterol binding sites of the drosophila melanogaster dopamine 
transporter in the human LAT1 transporter. (A) Sequence alignment of the cholesterol/CHS binding sites 
I (purple) and site II (red) from dDAT and human LAT1. Identical residues are scored with an asterix (*), 
equivalent residues with a plus (+) and similar residues scored on a scale from 1–9, with 1 being variable and 9 
being the maximal level of similarity. (B) Sequence comparison of the amino acid residues of site 1 and site 2 of 
the cholesterol binding sites of human LAT1 to orthologues. A conservation is given below each residue.
www.nature.com/scientificreports/
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Two well-characterised eukaryotic transporters, that have the LeuT fold, are the serotonin and dopamine 
transporters. Both have established interactions with cholesterol, and so we tested to see if LAT1 also has this 
feature. We found, following acute cholesterol depletion that LAT1 mediated kinetics of L-DOPA uptake were 
altered, with a decrease in Vmax but no change in the Km. This is consistent with a reduced maximal transport 
activity but without discernible change in substrate affinity. The depletion of cholesterol has been found to also 
result in reduced activity for the hDAT24 which led us to further investigate the mechanism of this modulation, to 
determine whether it is common between the two transporters.
Biochemical studies have suggested that cholesterol can either stabilise or induce the outward conformation 
for the hDAT and hSERT23,25. In the crystal structures of dDAT and hSERT, both transporters are bound to 
cholesterol and or CHS in the outward open conformation26–28. To determine whether the modulation of LAT1 
activity we observed was mediated indirectly by changes in membrane fluidity, for example, or whether it was 
through a direct interaction, LAT1 was purified. We found that the LAT1-CD98 heterodimer in the presence of 
CHS was stable and was further stabilised by a ligand, suggesting the complex was natively folded. In contrast, 
the heterodimeric complex could not be purified in the absence of CHS. The HPLC-SEC based thermostability 
assay utilised here, is a similar approach to that used for the GABA receptor to determine the binding constants 
of known ligands and identify a novel agonist for this receptor36. This approach may prove useful in establishing 
interactions of LAT1-CD98 with known LAT1 ligands and novel compounds, with the intention of inhibiting 
LAT1 for cancer treatment or to enhance brain penetration of compounds37,38.
Extensive work on GPCRs has revealed two mechanisms by which CHS potentially stabilises membrane pro-
teins, namely through the modulation of the geometry of detergent micelles or through direct interaction with 
the protein39. CHS is required for purification of a stable LAT1-CD98 complex suggesting either or both of the 
mechanisms above are relevant. A sequence comparison of dDAT and LAT1 reveals conservation of residues that 
could form two putative cholesterol/CHS binding sites. The conservation of these sites across LAT1 orthologues 
lends credence to the functional importance of these putative binding sites. Taken together, we conclude from 
these data that cholesterol modulates the activity of LAT1, and does so most likely through a direct interaction.
For some membrane proteins, a cholesterol/CHS interaction has been proposed to occur through choles-
terol interacting domains referred to as CRAC/CARC domains40. CRAC and CRAC-like motifs, are very differ-
ent when compared with the putative cholesterol/CHS binding sites identified in LAT1 through homology with 
dDAT. Unlike the CRAC motif, in which the residues essential for cholesterol interaction are contiguous, the 
cholesterol/CHS interacting residues of dDAT are separated in sequence space and can be proximal in 3D space26. 
Annotation of our predictive model of the LAT1 structure shows that the residues of the putative binding sites are 
on adjacent transmembrane helices which is similar in arrangement to dDAT. Furthermore, the recently solved 
structure of hSERT28 found CHS bound through a motif that conforms neither to the CRAC motif nor the two 
dDAT binding sites.
When LAT1 was overexpressed in the HEK293 cells we found that CD98 was upregulated. This has been noted 
by a number of previous studies and occurs by an unknown mechanism32,33,41. Our study found no evidence to 
suggest that LAT1 exists as a monomer in mammalian cells as the three fractions isolated and tested from the 
purification on a western blot all contained CD98. This shows that a lack of CD98 was not the reason for the 
instability found in SEC peaks 1 and 2. This is an important aspect to consider as LAT2 shares 52% amino acid 
Figure 6. Comparison of the putative cholesterol binding site residues of LAT1 versus the LAT2 
transporter sequence. Sequence alignment of the putative cholesterol/CHS binding sites I (purple) and site II 
(red) from human LAT1 and LAT2. Identical residues are scored with an asterix (*), equivalent residues with a 
plus (+) and similar residues scored on a scale from 1–9, with 1 being variable and 9 being the maximal level of 
similarity.
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identify with LAT1 and has been shown to be stabilised by its interaction with CD9819. A report concerning the 
LAT2-CD98 complex found that the addition of lauryl maltose neopentyl glycol and CHS during the purification 
stabilised the complex by an unknown mechanism42. However, the individual importance or otherwise of the 
LMNG and CHS was not individually tested42. Given the conservation between LAT1 and LAT2, it would be 
interesting to determine the effects of CHS on thermal and kinetic stability of LAT2 and of cholesterol depletion 
in cells on the kinetics of LAT2 uptake.
The closest LAT1 homologue in prokaryotes is the antiporter for serine/threonine SteT that has had mecha-
nistic information determined through the use of single molecule force spectroscopy43. This has found that ligand 
binding enhanced the kinetic stability and increased the flexibility of the transporter compared to the unbound 
form. In our study the addition of leucine enhanced the thermostability of the LAT1-CD98 complex but how 
this effects the rigidity of the complex is unknown. This is difficult to predict for the unbound or substrate bound 
Figure 7. Location of the putative cholesterol binding sites on the predictive 3D model of LAT1. (A) Crystal 
structure of dDAT (PDB: 4xpf) bound to cholesterol (yellow and red spheres) (B) Predictive 3D structure of 
LAT1 generated by the I-TASSER server and optimised to improve backbone stereochemistry. Key residues 
in the cholesterol/CHS binding sites I (purple) and II (red) of dDAT and the corresponding residues in the 
putative sites of LAT1 are shown as sticks.
www.nature.com/scientificreports/
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forms of LAT1-CD98 due to the additional complexity of the heterodimeric nature of the transporter compared 
to SteT.
In this present study we have taken advantage of the cholesterol interacting properties of cyclodextrin deriv-
atives. Methyl-β-cyclodextrin forms dimers each of which interacts with a cholesterol molecule, extracting it 
from the plasma membrane44. Sulfobutylether-β-cyclodextrin is unable to homodimerise and as a result does not 
remove cholesterol from the plasma membrane. In our experiments the transport of L-DOPA in LAT1 transfected 
cells was unaffected by incubation with sulfobutylether-β-cyclodextrin. Given the hydrophilic succinate moiety 
of the CHS, we presumed that methyl-β-cyclodextrin was unsuitable for depletion of CHS from the LAT1-CD98 
complex purified in the presence of CHS. Cyclodextrins have a number of proposed pharmacological uses. A 
cyclodextrin derivative has recently been proposed as a treatment option to promote atherosclerosis regression by 
removal of plaques45 and they are used as pharmacology excipients. In the current study we have not investigated 
in vivo but it would be interesting to do so in the future due to the potential effect on nutrient transport of these 
cyclodextrin derivatives utilised in treatment regimens.
In summary, we have been able to address some fundamental questions involving LAT1-CD98 interaction 
with cholesterol and how this affects stability and kinetic values. This should facilitate structural studies of LAT1 
that will ultimately be able to define how the transport cycle progresses at atomic/chemical level and the role of 
cholesterol in these processes.
Methods
Materials. Tritium labelled L-DOPA was acquired from Moravek (California, USA) with a specific activity of 
3.6 Ci/mmol. The V5 resin and V5 peptide were obtained from Biotool (Houston, USA). Cholesteryl hemisucci-
nate tris (CHS) and n-dodecyl beta maltoside (DDM) detergents were purchased from Generon (Maidenhead, 
UK). All other regents and chemicals, unless otherwise stated, were purchased from Sigma (Poole, Dorset, UK).
Cell Culture. HEK293 (ATCC, Middlesex, UK) and HEK293S GnTIˉ (HEK293SG, ATCC), were cultured 
adherently in high glucose Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10% v/v Foetal 
Bovine Serum (FBS). The cells were incubated at 37 °C with 5% CO2 and passaged every two to three days. 
HEK293 pcDNA3.1 (control) and HEK293 pcDNA3.1 LAT1-V5-His6 (LAT1) stable cell lines were previously 
generated by lipofectamine 2000 transfection, G418 treatment and single cell cloning3. Suspension cultures of 
HEK293S GnTIˉ cells stably overexpressing LAT1 were seeded from adherent cultures and maintained in either 
1 or 1.5 L of media in spinner flasks at 150 rpm. The suspension culture medium was composed of MEM Joklik 
modification with the addition of 13.4 mM glucose, 24 mM sodium bicarbonate, 10% w/v primatone, 1% w/v 
pluronic and 5% v/v FBS. Harvesting of the suspension cultures was done every four days for the HEK293S GnTIˉ 
LAT1 cells.
MβCD treatment, cholesterol quantification and cell surface preparation. To deplete cholesterol, 
the HEK293 cells were treated with serum free DMEM ± 10 mM methyl-β-cyclodextrin (MβCD) for 1 hour at 
37 °C with 5% CO2. Cells were used for drug uptake assay, cell surface preparation or total cholesterol quantifica-
tion (cholesterol/cholesteryl ester).
The cholesterol quantification assay (ab65359, Abcam, Cambridge, UK) was used with fluorometric parame-
ters according to manufacturer’s protocol. In brief, lipids were extracted from cells with chloroform: isopropanol: 
NP-40 (7:11:0.1), pelleted and organic phase air dried. Assay was performed in the presence of cholesterol ester-
ase with florescence measured on a microplate reader with 535 nm excitation and 595 nm emission filters.
To isolate cell surface proteins, a cell surface protein isolation kit, (Thermo Scientific) based on biotinylation 
and affinity binding to NeutrAvidin resin was used as previously described46.
Drug uptake. Functional drug uptake assays were performed using tritium labelled levodopa (3[H]-L-DOPA) 
as a tracer at 0.15 μCi/mL in transport medium (0.01 μM to 2 mM unlabelled L-DOPA; 25 mM HEPES, pH 7.4; 
Hank’s buffered saline solution (HBBS); 0.1% w/v BSA). The various HEK293 cell-lines were seeded 24 hours 
before the assay. Medium was aspirated and cells washed with HBBS, before transport medium, warmed to 37 °C 
was added. At the end of the assay, the transport medium was aspirated off and transport stopped by washing cells 
with ice cold HBBS three times. Cells were lysed by incubating at 37 °C in 5% w/v SDS for 30 minutes. The amount 
of radiation in the lysates was measured by liquid scintillation in disintegrations per minute which were used to 
calculate the amount of L-DOPA taken up as pmoles/million cells.
Immunoaffinity purification. HEK293S GnTIˉ LAT1 cell pellets were retrieved from cryostorage and 
thawed on ice in lysis buffer (10% v/v glycerol; Dulbecco’s phosphate buffered saline, pH 7; protease inhibitor tab-
lets (Pierce)). Thawed cells were lysed with a TissueRuptor (Qiagen) followed by sonication. Cell nuclei and debris 
were removed by centrifugation at 23,500 g for 20 minutes. The supernatant was then ultracentrifuged at 100,000 g 
for 1.5 hrs to isolate the membrane fraction from the soluble cytosolic fraction. The membranes were suspended 
by dounce homogeniser for solubilisation in TBS1 (1.5% w/v DDM, 20 mM Tris-Cl, 300 mM NaCl, and 10% w/v 
glycerol at pH 8 in the absence or presence of CHS). Solubilisation was performed overnight, concomitantly 
with V5 affinity gel incubation. The fraction of the solubilisation suspension not bound to the affinity gel, was 
removed by decanting the supernatant after centrifugation at 1500 g for 2 minutes. Resin was then washed in SEC 
buffer with DDM above CMC, 100 mM Tris-Cl, 300 mM NaCl, and 10% w/v glycerol at pH 8 in the absence or 
presence of CHS. LAT1-CD98 was eluted by incubating the washed resin with V5 peptide. Further purification 
was performed by size exclusion chromatography on a Superdex 200 10/300 column (GE Healthcare). The puri-
fied protein was concentrated using a 100 kDa cut-off polyethersulfone centrifugal filter and the pure protein 
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concentration calculated as follows; A280/ε with ε = 1.331, calculated from combined primary sequence of LAT1 
and CD98 by ExPASy ProtParam47.
Immunoblotting. Protein samples were incubated at room temperature in SDS loading buffer (0.5 M 
Tris-Cl; 30% v/v glycerol; 10% v/v SDS; 0.012% w/v bromophenol blue) before loading on to 12.5% Tris-glycine 
SDS-PAGE gels. Dithiothreitol or β-mercaptoethanol was included in the loading buffer when reducing con-
ditions were required. 20–40 μg total protein was loaded per well for cell-lysates and 5 μL from analysis of 
LAT1-CD98hc purifications. Gels were run at 200 V for 1 hr and proteins transferred from gel to PVDF mem-
branes by wet blotting at 100 V for 1.5 hrs. The membranes were blocked in 5% w/v semi-skimmed milk. 
Immunoblots were incubated with anti-His6 mouse monoclonal antibody (1:1000; Abcam) or anti-CD98 rabbit 
polyclonal antibody (1:1000; H300 Santa Cruz) or α 1 sodium potassium ATPase mouse monoclonal antibody 
(1:2000, clone 464.6 Abcam). Visualisation was done using anti-mouse or anti-rabbit HRP conjugated secondary 
antibodies by chemiluminescence.
Thermostability experiments. LAT1-CD98 was purified in SEC buffer and the fractions corresponding 
to the heterodimer were pooled, concentrated and analysed by HPLC-SEC. To determine the thermal stabil-
ity of LAT1-CD98, the protein in the desired buffer conditions, was incubated at a range of temperatures for 
10 minutes. 3 to 5 μg of protein from each sample were injected and analysed using the BIO-SEC5 HPLC column 
(Agilent). The peak height at A220 was normalised by dividing by the peak area and expressed as a fraction of the 
normalised peak height at 4 °C. This is referred to as the normalised absorbance. Normalised absorbance was 
plotted against temperature and the data analysed by a non-linear regression to the Boltzmann sigmoidal func-
tion using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, USA).
In silico protein structure modelling and conservation analysis. The amino acid sequences for 
human LAT1 and the Drosophila melanogaster dopamine transporter (dDAT) (NCBI accession numbers 
NP_003477.4 and NP_523763.2 respectively) were aligned using PROMALS3D34. The alignment was used to 
identify residues in cholesterol binding sites I & II of the dDAT that were conserved in LAT1, thus defining puta-
tive cholesterol binding sites in LAT1. An alignment of LAT1 orthologous sequences and LAT2 (Uniprot idenit-
fier:Q9UHI5-1) was performed using Clustal O48 to determine whether the putative cholesterol binding sites are 
conserved between orthologues. Orthologues were chosen from Canis lupus familiaris, Bos Taurus, Rattus nor-
vegicus, Mus musculus, Gallus gallus, Danio rerio, Drosophila melanogaster, and Xenopus tropicalis. (NCBI acces-
sion numbers XP_850176.2, NP_777038.1, NP_059049.1, NP_035534.2, NP_001025750.1, NP_001121830.1, 
NP_001245996.1, and NP_001135465.1 respectively). Annotation and scoring of conservation at each position 
was done in Jalview49, residues in binding site I & II were annotated in purple and red respectively. A model of 
LAT1 was generated in order to determine the proximity in space, of the residues in the putative binding sites. 
The best I-TASSER server50 generated 3D model of LAT1 was optimized using Modrefiner51 to improve backbone 
stereochemistry as assessed by Ramachandran plot analysis using RAMPAGE. Residues in putative binding sites 
were annotated on the resulting predicted structure in purple and red for sites I & II respectively.
Statistical tests & kinetic calculations. All statistical tests were performed with GraphPad Prism 6. For 
two different conditions, a two tailed t-tests was performed while for multiple comparisons an ANOVA with post 
hoc Tukey’s test was carried out.
Kinetics of L-DOPA uptake were determined by selecting a time point when linear transport was occurring 
and then subtracting the drug accumulation in HEK293 control cells from drug accumulation in HEK293 LAT1 
cells. This provides the LAT1 mediated fraction. Vmax was calculated by plotting the rate of drug transport by 
LAT1 (pmoles/min/million cells) against L-DOPA concentration (μM). GraphPad Prism 6 was used to calculate 
Michaelis–Menten values for LAT1 mediated L-DOPA uptake.
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